| Prostate cancer is the threat to the health of the common cancer of men. In 2002, there were 679,000 new cases worldwide, ranked No.2 man tumors [1], and its morbidity is still increasing. Prostate cancer morbidity has great areas, ethnic differences, in addition, the accuracy of diagnosis, the integrity of tumor registration and medical coverage also affect the final report of the disease. National Cancer Center SEER (Surveillance Epide-miology and End Results) database with complete information on the population and long-term follow-up, by 1975 to 2003 cancer data analysis helps to understand the morbidity of prostate cancer trends and characte-ristics of it . The United States from 2000 to 2003 the morbidity of prostate cancer in men 170.3/10 million, and has a significant ethnic differences:black man 258.3/10 million, higher than the white 163.4/10 million, the lowest in Asia and the Pacific Islands ethnic origin to 96.8/10 million. Prostate cancer morbidity increased gradually with age,≥65-year-old male high morbidity of 938.5/10 million,<65-year-old only 59.2/10 million.2000 to 2003 the U.S. prostate cancer mortality 27.4/10 million black people (59.1/10 million) was significantly higher than whites (26.3/10 million) and the Asian and Pacific Islander ethnic group (12.2/10 million). International Agency for Research on Cancer information in China in 2002 of prostate cancer standardized morbidity was 1.6/10 million, mortality rate was 1.0/10 million, is a low-risk countries in prostate cancer . Currently the morbidity of prostate cancer increased year by year, cases constitute is mainly to the late, while there is a big gap in the diagnosis and treatment compared with the U.S., thus improving the diagnosis and treatment of prostate cancer is important. In the early stages of prostate cancer, (that is confined to the prostate), symptoms are generally silent. In fact, some of the mild urinary symptoms that patients may experience typically come from concomitant/unrelated BPH and are not attributable to the cancer that may also exist. Again, it should be emphasized that in early stages of prostate cancer, tehre are typically no symptoms. When the cancer becomes more extensively involved to the prostate, urinary symptoms may then develop. The lack of any symptoms in prostate cancer emphasizes the important role of screening measures in all patients regardless of symptoms. In most patients with prostate cancer (especially localized prostate cancer) patients will usually have no symptoms. The most common symptoms of prostate cancer do occur in advanced disease, particularly when it involves the bones. Persistent and often severe pain in the back, hips or other bones is characteristic. Treatment is dependent on the stage, grade, patient age, and health status and patient preference. Treatments for localized cancer (stage T1, T2) include surgery (radical prostatecomy), radiation therapy (either external beam radiation or brachytherapy or seeds), or perhaps in certain cases, no therapy at all (watchful waiting). Patients with more advanced disease are typically treated with hormonal therapy. Again, the precise treatment strategy should be individualized for each patient after counseling with his urologist.Types of clinical cancer are clinical cancer, latent cancer, adventitions cancer. Latent cancer is also known as health cancer, because neither of these prostate cancer is life-threatening, it will not affect the patients quality of life, so these patients do not need any treatment, while the real fatal prostate cancer accounts for only 3.6% of the total, That is, only that 3.6% of prostate cancer patients really need treatment, so in the clinical treatment of prostate cancer first need to accurately identify what type of prostate cancer, and then other specific situations depending on the patient's individual development of effective treatment plan, would also avoid unnecessary over-treatment, because of over-treatment is not only a waste of manpower and financial resources, but can also bring to the patients serious consequences such as impotence, premature ejaculation, sexual dysfunction, osteoporosis, etc., Although there are many domestic and international researches in prostate cancer, there are very little understanding of molecular markers for Prostate Cancer Prognosis. and the researches in different countries and in different races will inevitably lead to somewhat different results somewhat, and molecular markers of prostate cancer biological characteristics and prognosis The determination and treatment of prostate cancer guidance plays an important role. This study is about the discussion of prognosis molecular markers (MUC-1 and Claudin-4) of prostate cancer.Objective:To investigate the expression and clinical significances of MUC-1 and Claudin-4 protein in prostate carcinoma,and evaluate if it could be aprostate molecular marker in prostate cancer.Methods:3rd Gen ImmunohistochemistryResults:(一)MUC-1 The positive staining rates of MUC-1 protein expression were 54.3% and 55.6% in patients with prostate cancer and benign prostate hyperplasia respectively.There was no significant expres-sion(P>0.05);the positive staining rates of MUC-1 protein expression were 53.3% and 52.9% in prostate cancer with different pathology stage (A-Cstage and D stage)respectively. There was no significant expression (P>0.05);The positive staining rates of MUC-1 protein expression were 54.5% and 54.2% in prostate cancer with different pathology grade(Gleason scores≤7 and Gleason scores＞7)respectively. There was no significant expression(P>0.05);The positive staining rates of MUC-1 protein expres-sion were 50% and 57.1% in prostate cancer patients with different PSA value(PSA≤20 and PSA＞20)respectively, there was no significant expres-sion(P>0.05); The positive staining rates of MUC-1 protein expression were 58.8% and 56.25% in prostate cancer with different endocrine therapy effect(good curative effect and bad curative effect),There was no significant expression(P>0.05);The survival time of prostate cancer who had negative MUC-1 expression was not longer than that who had positive MUC-1 expression by Log Rank analyses(P>0.05).(二) Claudin-4 The positive staining rates of Claudin-4 protein expression were 88.6% and 77.8% in patients with prostate cancer and benign prostate hyperplasia respectively.The Claudin-4 expression was significantly higher in prostate cancer than that in benign prostate hyperplasia (P<0.05);The positive staining rates of Claudin-4 protein expression were 73.3% and 100% in prostate cancer with different patho-logy stage (A-Cstage and D stage)respectively. The Claudin-4 expression was significantly higher in D stage prostate cancer than that in A-C stage prostate cancer. (P<0.05);The positive staining rates of CIaudin-4 protein expression were 100% and 83.3% in prostate cancer with different pathology grade(Gleason scores≤7 and Gleason scores＞7) respectively. There was no significant expression(P>0.05);The positive staining rates of Claudin-4 protein expression were 83.3% and 92.9% in prostate cancer patients with different PSA value(PSA≤20 and PSA＞20) respectively, there was no significant expression(P>0.05); The positive staining rates of Claudin-4 protein expression were 82.4% and 93.75% in prostate cancer with different endocrine therapy effect(good curative effect and bad curative effect),There was no significant expression(P>0.05);The survival time of prostate cancer who had negative Claudin-4 expression was not longer than that who had positive Claudin-4 expression by Log Rank analyses(P>0.05).
|
PDF Full Text Request